These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22529468)

  • 1. Chemically modified tetracyclines: Novel therapeutic agents in the management of chronic periodontitis.
    Agnihotri R; Gaur S
    Indian J Pharmacol; 2012 Mar; 44(2):161-7. PubMed ID: 22529468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemically modified tetracyclines: The novel host modulating agents.
    Swamy DN; Sanivarapu S; Moogla S; Kapalavai V
    J Indian Soc Periodontol; 2015; 19(4):370-4. PubMed ID: 26392682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periodontal therapeutics: Current host-modulation agents and future directions.
    Golub LM; Lee HM
    Periodontol 2000; 2020 Feb; 82(1):186-204. PubMed ID: 31850625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nonantimicrobial properties of tetracycline for the treatment of periodontal disease.
    Vernillo AT; Ramamurthy NS; Golub LM; Rifkin BR
    Curr Opin Periodontol; 1994; ():111-8. PubMed ID: 8032451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemically modified tetracyclines an emerging host modulator in chronic periodontitis patients: A randomized, double-blind, placebo-controlled, clinical trial.
    Alyousef AA; Divakar DD; Muzaheed
    Microb Pathog; 2017 Sep; 110():279-284. PubMed ID: 28687322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking Periodontal Disease Progression by Inhibiting Tissue-Destructive Enzymes: A Potential Therapeutic Role for Tetracyclines and Their Chemically-Modified Analogs.
    Rifkin BR; Vernillo AT; Golub LM
    J Periodontol; 1993 Aug; 64 Suppl 8S():819-827. PubMed ID: 29539753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines.
    Ramamurthy NS; Rifkin BR; Greenwald RA; Xu JW; Liu Y; Turner G; Golub LM; Vernillo AT
    J Periodontol; 2002 Jul; 73(7):726-34. PubMed ID: 12146531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs.
    Rifkin BR; Vernillo AT; Golub LM
    J Periodontol; 1993 Aug; 64(8 Suppl):819-27. PubMed ID: 8410621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives.
    Grenier D; Plamondon P; Sorsa T; Lee HM; McNamara T; Ramamurthy NS; Golub LM; Teronen O; Mayrand D
    J Periodontol; 2002 Jan; 73(1):79-85. PubMed ID: 11846203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxin-induced periodontal breakdown in rats.
    Llavaneras A; Ramamurthy NS; Heikkilä P; Teronen O; Salo T; Rifkin BR; Ryan ME; Golub LM; Sorsa T
    J Periodontol; 2001 Aug; 72(8):1069-77. PubMed ID: 11525440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-antimicrobial properties of tetracyclines--dental and medical implications.
    Rawal SY; Rawal YB
    West Indian Med J; 2001 Jun; 50(2):105-8. PubMed ID: 11677904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases.
    Golub LM; Elburki MS; Walker C; Ryan M; Sorsa T; Tenenbaum H; Goldberg M; Wolff M; Gu Y
    Int Dent J; 2016 Jun; 66(3):127-35. PubMed ID: 27009489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Chemically Modified Tetracyclines in the Management of Periodontal Diseases: A Review.
    Ghangurde AA; Ganji KK; Bhongade ML; Sehdev B
    Drug Res (Stuttg); 2017 May; 67(5):258-265. PubMed ID: 28268238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs.
    Golub LM; Ramamurthy NS; McNamara TF; Greenwald RA; Rifkin BR
    Crit Rev Oral Biol Med; 1991; 2(3):297-321. PubMed ID: 1654139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation.
    Gu Y; Lee HM; Sorsa T; Salminen A; Ryan ME; Slepian MJ; Golub LM
    Pharmacol Res; 2011 Dec; 64(6):573-9. PubMed ID: 21771657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host modulation with tetracyclines and their chemically modified analogues.
    Golub LM; Suomalainen K; Sorsa T
    Curr Opin Dent; 1992 Mar; 2():80-90. PubMed ID: 1325849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities.
    Tilakaratne A; Soory M
    Open Dent J; 2014; 8():109-24. PubMed ID: 24976875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the host response in the treatment of periodontitis.
    Golub LM; Ryan ME; Williams RC
    Dent Today; 1998 Oct; 17(10):102-6, 108-9. PubMed ID: 10752438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Host-response therapeutics for periodontal diseases.
    Giannobile WV
    J Periodontol; 2008 Aug; 79(8 Suppl):1592-600. PubMed ID: 18673015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tetracyclines on bone metabolism.
    Vernillo AT; Rifkin BR
    Adv Dent Res; 1998 Nov; 12(2):56-62. PubMed ID: 9972123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.